JP2024515240A5 - - Google Patents
Info
- Publication number
- JP2024515240A5 JP2024515240A5 JP2023561645A JP2023561645A JP2024515240A5 JP 2024515240 A5 JP2024515240 A5 JP 2024515240A5 JP 2023561645 A JP2023561645 A JP 2023561645A JP 2023561645 A JP2023561645 A JP 2023561645A JP 2024515240 A5 JP2024515240 A5 JP 2024515240A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nucleic acid
- acid molecule
- hla
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171672P | 2021-04-07 | 2021-04-07 | |
| US63/171,672 | 2021-04-07 | ||
| PCT/US2022/023685 WO2022216832A1 (en) | 2021-04-07 | 2022-04-06 | A composition for use in treating mhc-1-opathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515240A JP2024515240A (ja) | 2024-04-08 |
| JP2024515240A5 true JP2024515240A5 (https=) | 2025-03-21 |
Family
ID=81580496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561645A Pending JP2024515240A (ja) | 2021-04-07 | 2022-04-06 | Ｍｈｃ－ｉ病の治療に使用するための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12370257B2 (https=) |
| EP (1) | EP4320166A1 (https=) |
| JP (1) | JP2024515240A (https=) |
| KR (1) | KR20230167355A (https=) |
| CN (1) | CN117321084A (https=) |
| AU (1) | AU2022256043A1 (https=) |
| CA (1) | CA3215902A1 (https=) |
| IL (1) | IL306046A (https=) |
| MX (1) | MX2023011720A (https=) |
| WO (1) | WO2022216832A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL248777B1 (pl) * | 2024-03-05 | 2026-01-26 | Inst Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk | Sposób określania ciężkości reumatoidalnego zapalenia stawów na podstawie pomiaru stężenia białka ERAP2 |
| CN118047824B (zh) * | 2024-04-01 | 2024-06-28 | 北京瑞博奥医药科技有限公司 | 二烷基膦酸在寡核苷酸合成中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2804763C (en) | 2010-07-14 | 2023-01-03 | The Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| US8969254B2 (en) | 2010-12-16 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2013162368A1 (en) | 2012-04-26 | 2013-10-31 | Stichting Vu-Vumc | Biomarkers |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| KR101748867B1 (ko) | 2013-04-19 | 2017-06-20 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 자동화 시스템 |
| US20160145687A1 (en) | 2013-06-25 | 2016-05-26 | Turun Yliopisto | Method of Predicting Risk for Type 1 Diabetes |
| US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
| US10927412B2 (en) | 2013-10-01 | 2021-02-23 | The Regents Of The University Of California | Endometriosis classifier |
| US10166210B2 (en) | 2014-06-12 | 2019-01-01 | Nsabp Foundation, Inc. | Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin |
| EP3730188B1 (en) | 2015-08-21 | 2024-07-31 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| GB201609712D0 (en) | 2016-06-03 | 2016-07-20 | Babraham Inst | Disease targets and biomarkers |
| US20190375842A1 (en) | 2018-01-04 | 2019-12-12 | Vanderbilt University | Check point inhibition in organ fibrosis |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11632728B2 (en) | 2019-07-18 | 2023-04-18 | Qualcomm Incorporated | Directional measurements for sidelink synchronization signal transmission |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| WO2021113805A1 (en) | 2019-12-05 | 2021-06-10 | The General Hospital Corporation | Multi-biomarker prediction models for multiple infection episodes following blunt trauma |
-
2022
- 2022-04-06 JP JP2023561645A patent/JP2024515240A/ja active Pending
- 2022-04-06 WO PCT/US2022/023685 patent/WO2022216832A1/en not_active Ceased
- 2022-04-06 KR KR1020237032803A patent/KR20230167355A/ko active Pending
- 2022-04-06 AU AU2022256043A patent/AU2022256043A1/en active Pending
- 2022-04-06 IL IL306046A patent/IL306046A/en unknown
- 2022-04-06 EP EP22721534.0A patent/EP4320166A1/en active Pending
- 2022-04-06 US US17/714,717 patent/US12370257B2/en active Active
- 2022-04-06 CA CA3215902A patent/CA3215902A1/en active Pending
- 2022-04-06 CN CN202280026149.XA patent/CN117321084A/zh active Pending
- 2022-04-06 MX MX2023011720A patent/MX2023011720A/es unknown
-
2025
- 2025-06-25 US US19/249,070 patent/US20250375519A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250115907A1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| ES2629747T3 (es) | Inducción de la omisión de exones en células eucarióticas | |
| US10767178B2 (en) | Compositions and methods of using piRNAS in cancer diagnostics and therapeutics | |
| JP7531514B2 (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| JP2021091737A (ja) | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 | |
| TW202018081A (zh) | 用於B型肝炎病毒感染之RNAi藥劑 | |
| JP2018527013A (ja) | アレル選択的な遺伝子編集およびその使用 | |
| JP2002272489A5 (https=) | ||
| JP2009537129A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| JP2024515240A5 (https=) | ||
| TW201209163A (en) | Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3 | |
| JP2023536437A5 (https=) | ||
| Jaschinski et al. | Design and selection of antisense oligonucleotides targeting transforming growth factor beta (TGF-β) isoform mRNAs for the treatment of solid tumors | |
| JP6286050B2 (ja) | トリインフルエンザウイルスのｍｉＲＮＡとその同定、検出および使用 | |
| US20180112218A1 (en) | Targeting Hepatitis B Virus (HBV) Host Factors | |
| TWI670064B (zh) | 抗病毒劑及治療病毒感染之方法 | |
| CN116889627A (zh) | 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 | |
| CA3237033A1 (en) | Methods of treating headaches and migraines with sodium voltage-gated channel alpha subunit 11 (scn11a) inhibitors | |
| US20230025878A1 (en) | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | |
| WO2004093778A2 (en) | Oligonucleotides that block toll-like receptors | |
| WO2013188824A2 (en) | Hexim-1 as a target of leptin signaling to regulate obesity and diabetes | |
| JP2022525456A5 (https=) | ||
| CN112779252B (zh) | 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸 | |
| US20230108957A1 (en) | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | |
| JP2025507279A5 (https=) |